Kei Nakata

Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts

Masashi Mizuno, Atsushi Kuno, Toshiyuki Yano et al. · Physiological Reports · 2018 · 168 citations · Full text

Life Sciences, Pharmacology, Physiology +9

Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats

H Oshima, Takayuki Miki, Atsushi Kuno et al. · Journal of Pharmacology and Experimental Therapeutics · 2018 · 127 citations · Full text

Medicine, Cardiology, Pharmacology +14

mTORC1 inhibition attenuates necroptosis through RIP1 inhibition-mediated TFEB activation

Koki Abe, Toshiyuki Yano, Masaya Tanno et al. · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2019 · 78 citations · Full text

Life Sciences, Cell Biology, Pharmacology +12

Canagliflozin, a sodium–glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats

Yukishige Kimura, Atsushi Kuno, Masaya Tanno et al. · Journal of Diabetes Investigation · 2019 · 57 citations · Full text

Medicine, Endocrinology, Pharmacology +17

[Effects of oxygen administration in sleep-induced apneas].

Kei Nakata, Naohiko Chonabayashi · PubMed · 1985 · 53 citations

Medicine, Otolaryngology, Physiology +12